Ken Fyvie

Cytomos Ltd. provides rapid label-free cell analysis for biotechnology research and in-vitro diagnostics using dielectric spectroscopy. The firm offers ePad technology which permits detection, identification, and characterization of single cells in real-time as they progress through an experiment. The company was founded by Keith Muir and is headquartered in Edinburgh, the United Kingdom.

Ten Bio Ltd. specializes in providing tailor-made solutions to help clients achieve progress in their skin research programs. The private company is based in Dundee, UK. The British company offers full-thickness human skin with dermal and epidermal layers, appendages, and minor skin cell populations. The company's human skin model, TenSkin™, responds like it would in vivo, delivering predictive results that contribute to a more efficient development process. The company was founded in 2019 by Robyn Hickerson and Michael Patrick Conneely, with Robyn Hickerson serving as CEO since then.

Cytomos Ltd. provides rapid label-free cell analysis for biotechnology research and in-vitro diagnostics using dielectric spectroscopy. The firm offers ePad technology which permits detection, identification, and characterization of single cells in real-time as they progress through an experiment. The company was founded by Keith Muir and is headquartered in Edinburgh, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

Ten Bio Ltd. specializes in providing tailor-made solutions to help clients achieve progress in their skin research programs. The private company is based in Dundee, UK. The British company offers full-thickness human skin with dermal and epidermal layers, appendages, and minor skin cell populations. The company's human skin model, TenSkin™, responds like it would in vivo, delivering predictive results that contribute to a more efficient development process. The company was founded in 2019 by Robyn Hickerson and Michael Patrick Conneely, with Robyn Hickerson serving as CEO since then.

Cytomos Ltd. provides rapid label-free cell analysis for biotechnology research and in-vitro diagnostics using dielectric spectroscopy. The firm offers ePad technology which permits detection, identification, and characterization of single cells in real-time as they progress through an experiment. The company was founded by Keith Muir and is headquartered in Edinburgh, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.